about
Metabolism of phosphatidylinositol 4-kinase IIIα-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activityModulation of CD14 and TLR4·MD-2 activities by a synthetic lipid A mimetic.Sugar-based inhibitors of Ras activation: biological activity and identification of Ras-inhibitor binding interface.Synthesis and biological evaluation of novel lipid A antagonists.First experimental identification of Ras-inhibitor binding interface using a water-soluble Ras ligand.Evidence of a specific interaction between new synthetic antisepsis agents and CD14.Toll-like receptor 4 (TLR4) modulation by synthetic and natural compounds: an update.Extending chemoselective ligation to sugar chemistry: convergent assembly of bioactive neoglycoconjugates.Chemoselective ligation in glycochemistry.Glycoconjugates in cancer therapy.TLR4 antagonist FP7 inhibits LPS-induced cytokine production and glycolytic reprogramming in dendritic cells, and protects mice from lethal influenza infection.Carbohydrate-based bioactive compounds for medicinal chemistry applications.Molecular simplification of lipid A structure: TLR4-modulating cationic and anionic amphiphiles.Chemistry of lipid A: at the heart of innate immunity.Functional characterization of E. coli LptC: interaction with LPS and a synthetic ligand.Glycolipid-based TLR4 Modulators and Fluorescent Probes: Rational Design, Synthesis, and Biological Properties.NS5A inhibitors impair NS5A-phosphatidylinositol 4-kinase IIIα complex formation and cause a decrease of phosphatidylinositol 4-phosphate and cholesterol levels in hepatitis C virus-associated membranes.Glial TLR4 receptor as new target to treat neuropathic pain: efficacy of a new receptor antagonist in a model of peripheral nerve injury in mice.Uniform lipopolysaccharide (LPS)-loaded magnetic nanoparticles for the investigation of LPS-TLR4 signaling.Design, synthesis, and biological evaluation of levoglucosenone-derived ras activation inhibitors.Novel alpha-conotoxins from Conus spurius and the alpha-conotoxin EI share high-affinity potentiation and low-affinity inhibition of nicotinic acetylcholine receptors.A novel small molecule TLR4 antagonist (IAXO-102) negatively regulates non-hematopoietic toll like receptor 4 signalling and inhibits aortic aneurysms development.Synthesis and biological evaluation of an anticancer vaccine containing the C-glycoside analogue of the Tn epitope.Structure-activity studies on arylamides and arysulfonamides Ras inhibitors.Clicked and long spaced galactosyl- and lactosylcalix[4]arenes: new multivalent galectin-3 ligands.Novel Tn antigen-containing neoglycopeptides: synthesis and evaluation as anti tumor vaccines.Synthesis and conformational analysis of novel N(OCH3)-linked disaccharide analogues.The Role of Carbohydrates in the Lipopolysaccharide (LPS)/Toll-Like Receptor 4 (TLR4) Signalling.Co-administration of Antimicrobial Peptides (AMPs) EnhancesToll-like Receptor 4 (TLR4) Antagonist Activity of a Synthetic Glycolipid.Design and characterization of a new class of inhibitors of ras activation.Recent advances on Toll-like receptor 4 modulation: new therapeutic perspectives.Amphiphilic Guanidinocalixarenes Inhibit Lipopolysaccharide (LPS)- and Lectin-Stimulated Toll-like Receptor 4 (TLR4) Signaling.TLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis.Toll-like receptor 4 modulation influences human neural stem cell proliferation and differentiation.Structure-Activity Relationship in Monosaccharide-Based Toll-Like Receptor 4 (TLR4) Antagonists.Synthetic and natural small molecule TLR4 antagonists inhibit motoneuron death in cultures from ALS mouse model.Chemoselective NeoglycosylationSynthesis of Imino Sugar Scaffolds for the Generation of Glycosidase Inhibitor LibrariesGlycoconjugate and oligosaccharide mimetics by chemoselective ligationPolycyclic scaffolds from fructose
P50
Q28481438-F9A86C73-10D9-4A14-B84D-85C8A07CEB58Q30715502-9D9811CA-A273-4798-B5FB-246F6B75572CQ30836943-B80E3C5B-9414-40AD-B5E6-23E2C8E11D4FQ33224532-E720186F-548C-40F5-A85B-FFA96B25C64CQ33465378-B77B0735-B4BF-4509-9591-B257877C360FQ33575108-1C09E295-82E1-4DD2-BF12-FD11F7DFB702Q33693637-C9D406BC-4EC4-4C4E-99EE-A9A24F541EC1Q35552161-7C759A52-130A-4910-9982-36BFAC265299Q35686574-32E128FB-D8CC-4410-8BCE-F87300205D36Q37065304-DB166A60-DEE6-47CD-AF43-871D971332A1Q37595395-038B693A-B59E-45C4-8DE8-AB3C6B27C57FQ37804889-7848A541-C2B5-4002-8C62-848AFC53D361Q38221081-323530CA-F4BF-4FC9-8500-85FDE72F4D93Q38263544-DE12F046-8DB6-4F74-B741-2E1A06EC633FQ38308149-2CFCA5E0-DFE0-41F8-9F49-784E83647DB6Q38792526-93E0C55D-7730-4625-BD91-97F80368C102Q38956355-6E0A6096-A190-4274-A682-B7AEF0C3ED23Q39317312-C86422D9-0C2E-4053-88B9-E6C0C2D556D4Q39608906-739605ED-24F8-4F19-942D-2FAD49B275A6Q39882242-62A74C5B-168F-4EC9-9759-21B6011D5DF2Q40106439-ADC886C4-8BFB-46A9-AD97-7E40EC3C64BEQ40595866-7930636E-A11D-4021-B7B7-D7B900D952A1Q40806114-3463C389-9021-4602-AF26-9321AFE897ADQ42830197-298205CC-F1F9-4915-8F62-8D71CBF7FE4CQ42837584-4925313D-F121-4234-A652-F32FBE72DBB0Q43911246-C25C02BF-8627-4F75-A1CA-FDDA4D9EF8F6Q44807973-F2E8348A-A73C-4073-9121-D4DA2315C370Q47147061-C5EF56F3-E161-4E19-961A-A143EDC2B490Q47266793-198B3047-5929-45B7-80A2-5593A8257C61Q47623449-E8B0B6CA-89C5-4A62-ACA1-62AC6715B683Q47705192-21A0F293-0DF8-4B5B-977E-D6814464A07FQ48191631-8DEDA11D-6400-474A-85C2-982680BEF542Q48641496-43576AB3-DC77-4E63-B185-DE7A75326D2CQ49958576-91B6DCFA-262B-4E84-9241-9C5541C1C84AQ52729647-3C35A62E-3AD3-4AC6-A34B-3E6464EBFEB1Q53391111-8F8DFCBD-D26C-454D-AFBB-392E863D4B75Q57363517-8C9AB480-32CC-42D7-8635-7282ABB559B5Q60167298-BB9C9D1C-4816-413B-8FEA-F9F305D1C318Q60167300-72D0CC49-BD62-45A9-A74A-C69B93205DC3Q60167303-986A690A-9B31-46AC-BA34-66462FED1930
P50
description
researcher ORCID ID = 0000-0002-3417-8224
@en
wetenschapper
@nl
name
Francesco Peri
@ast
Francesco Peri
@en
Francesco Peri
@es
Francesco Peri
@nl
type
label
Francesco Peri
@ast
Francesco Peri
@en
Francesco Peri
@es
Francesco Peri
@nl
prefLabel
Francesco Peri
@ast
Francesco Peri
@en
Francesco Peri
@es
Francesco Peri
@nl
P106
P21
P31
P496
0000-0002-3417-8224